Cabot (CBT)
(Delayed Data from NYSE)
$110.86 USD
-0.91 (-0.81%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $110.92 +0.06 (0.05%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$110.86 USD
-0.91 (-0.81%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $110.92 +0.06 (0.05%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
Zacks News
Arkema (ARKAY) Backs Tiamat for Lithium-Free Battery Innovation
by Zacks Equity Research
Arkema (ARKAY) invests in Tiamat, accelerating the development of lithium-free solutions and supporting the construction of a dedicated 5 GWh Giga-factory in France.
New Strong Buy Stocks for January 15th
by Zacks Equity Research
CBT, BROS, WRK, ROCK and CBOE have been added to the Zacks Rank #1 (Strong Buy) List on January 15, 2024.
Daqo (DQ) Issues Update on $700M Share Repurchase Program
by Zacks Equity Research
Daqo New Energy (DQ) repurchased shares worth $491 million by 2023 end, expressing confidence in undervaluation and emphasizing capital preservation amid industry challenges.
Here's Why Cabot (CBT) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain Nutrien (NTR) in Your Portfolio
by Zacks Equity Research
While Nutrien (NTR) faces challenges from softer fertilizer prices, it gains on strong demand for crop nutrients on the strength in global agriculture markets.
ArcelorMittal (MT) to Restart Bosnia Plant After Two-Month Halt
by Zacks Equity Research
ArcelorMittal (MT) plans to restart its Bosnia plant after a November shutdown due to declining steel demand in Europe, influenced by the Ukraine war and rising costs.
Celanese (CE) Gains on Acquisitions & Productivity Actions
by Zacks Equity Research
While Celanese (CE) faces headwinds from weaker demand and de-stocking, it benefits from productivity measures, investments in organic projects and strategic acquisitions.
Intrepid (IPI) Enters Into Third Amendment to Agreement With XTO
by Zacks Equity Research
Intrepid Potash (IPI) secures strategic gains with XTO Holdings, enhancing cooperation and shareholder value in the Designated Potash Area.
BASF (BASFY) & Stena Partner for Europe's EV Battery Recycling
by Zacks Equity Research
BASF (BASFY) and Stena Recycling will create a circular battery recycling system for European electric vehicles, emphasizing high metal recovery rates and a reduced carbon footprint.
Reliance Steel (RS) Shares Up 32% in a Year: What's Driving It?
by Zacks Equity Research
Reliance Steel (RS) benefits from strong underlying demand in its major markets and strategic acquisitions.
Innospec's (IOSP) Stock Up 14% in 3 Months: Here's Why
by Zacks Equity Research
Innospec (IOSP) benefits from the strength in its Oilfield Services unit and strategic growth measures.
Universal Stainless (USAP) Surges 76% in 3 Months: Here's Why
by Zacks Equity Research
The strong momentum in Universal Stainless' (USAP) stock reflects a stellar performance in the third quarter, primarily driven by record sales in the aerospace sector.
ArcelorMittal (MT) Rejects Italy Government's Stake Plan in ADI
by Zacks Equity Research
ArcelorMittal (MT) rejects the Italian government's proposal to acquire a controlling stake in ADI, a major steel plant, citing reluctance to commit financially, sparking concerns over the future of the financially troubled ex-Ilva plant in Taranto.
Here's Why You Should Buy Eastman Chemical (EMN) Stock Right Now
by Zacks Equity Research
Eastman Chemical (EMN) benefits from cost-management actions, operational execution and innovation.
Why Should You Add Air Products (APD) Stock to Your Portfolio
by Zacks Equity Research
Air Products (APD) benefits from its investments in high-return industrial gas projects, project wins and productivity initiatives.
Cabot (CBT) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Cabot (CBT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Cabot (CBT) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Cabot (CBT) have what it takes? Let's find out.
CBT or AIQUY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CBT vs. AIQUY: Which Stock Is the Better Value Option?
Is Cabot (CBT) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Hawkins (HWKN) Up 51% in 6 Months: What's Driving the Stock?
by Zacks Equity Research
Hawkins (HWKN) benefits from the robust Water Treatment segment, strategic acquisitions and a prudent pricing strategy.
CBT or AIQUY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CBT vs. AIQUY: Which Stock Is the Better Value Option?
Is Cabot (CBT) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Cabot (CBT) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cabot (CBT) Up 6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Cabot (CBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cabot (CBT) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?